TY - JOUR T1 - MET∆14 promotes a ligand-dependent, AKT-driven invasive growth JF - Life Science Alliance JO - Life Sci. Alliance DO - 10.26508/lsa.202201409 VL - 5 IS - 10 SP - e202201409 AU - Marina Cerqua AU - Orsola Botti AU - Maddalena Arigoni AU - Noemi Gioelli AU - Guido Serini AU - Raffaele Calogero AU - Carla Boccaccio AU - Paolo M Comoglio AU - Dogus M Altintas Y1 - 2022/10/01 UR - https://www.life-science-alliance.org/content/5/10/e202201409.abstract N2 - MET is an oncogene encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF). Upon ligand binding, MET activates multiple signal transducers, including PI3K/AKT, STAT3, and MAPK. When mutated or amplified, MET becomes a “driver” for the onset and progression of cancer. The most frequent mutations in the MET gene affect the splicing sites of exon 14, leading to the deletion of the receptor’s juxtamembrane domain (MET∆14). It is currently believed that, as in gene amplification, MET∆14 kinase is constitutively active. Our analysis of MET in carcinoma cell lines showed that MET∆14 strictly depends on HGF for kinase activation. Compared with wt MET, ∆14 is sensitive to lower HGF concentrations, with more sustained kinase response. Using three different models, we have demonstrated that MET∆14 activation leads to robust phosphorylation of AKT, leading to a distinctive transcriptomic signature. Functional studies revealed that ∆14 activation is predominantly responsible for enhanced protection from apoptosis and cellular migration. Thus, the unique HGF-dependent ∆14 oncogenic activity suggests consideration of HGF in the tumour microenvironment to select patients for clinical trials. ER -